Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Resalis Therapeutics logo — Tackling metabolic disorders with non-coding RNAs

Resalis Therapeutics

Tackling metabolic disorders with non-coding RNAs

Founded 2021 Italy Italy 10 employees Series A Total: $26.00M Biotechnology, Health Care +2

General Information

Company Name Resalis Therapeutics
Founded Year 2021
Location Italy Italy +1
Employees 10
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Series A
Social

Get notified when Resalis Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Resalis Therapeutics

Resalis Therapeutics is a biotechnology startup that is determined to address metabolic disorders through non-coding RNAs. The company's focus lies in targeting a master regulator of key pathways underlying obesity and fatty liver disease. Their lead program, RES-010, aims to provide a safe and convenient treatment offering substantial therapeutic impact, including durable weight loss and reduction of hepatic steatosis, with a unique understanding of the non-coding RNA drug modality and lipid metabolism. Founded in 2021 and headquartered in Italy, Resalis Therapeutics has received a significant €10.00M Series A investment on 04 January 2024 from notable investors Sunstone Capital and Claris Ventures. With robust preclinical evidence, the company is well-positioned to advance RES-010 into clinical trials for a range of metabolic disorders. This innovative approach to tackling metabolic diseases and the strategic investment support indicates the potential for Resalis Therapeutics to make a meaningful impact in the biotechnology and pharmaceutical industries.

Taxonomy: metabolic disorders, non-coding RNAs, drug modality, lipid metabolism, obesity, fatty liver disease, therapeutic impact, weight loss, hepatic steatosis, clinical trials, preclinical evidence, disease-modifying, metabolic disease, RES-010, Resalis Therapeutics

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 2
Investor
•••• •••• 		04 Jan 2024
Seed Round •••••• 3
Investor Investor
•••• •••• 		22 Feb 2023
Seed Round •••••• 3
Investor Investor
•••• •••• 		05 Aug 2021

Latest News

View All
Torino-based Resalis raises €10 million Series A to provide a therapeutic that reduces fat mass in o... — Eu-startups
Torino-based Resalis raises €10 million Series A to provide a therapeutic that reduces fat mass in obesity
Eu-startups Jan 23, 2024

Resalis Therapeutics Alternatives & Competitors

Resalis Therapeutics vs
Avolynt, Inc.
Avolynt, Inc.

Avolynt is a clinical stage pharmaceutical company developing novel therapeutics for the treatment o...

Grant
2 employees
Biotechnology, Health Care
Resalis Therapeutics vs
Ember Therapeutics
Ember Therapeutics United States

Ember Therapeutics is a product-focused company translating its world-class biology in the emerging...

Series A
6 employees
Biotechnology, Health Care
Resalis Therapeutics vs
AZAFAROS B.V.
AZAFAROS B.V. The Netherlands

Navigating towards new treatment options for rare metabolic diseases

Series B
25 employees

FAQ About Resalis Therapeutics

Tackling metabolic disorders with non-coding RNAs
Resalis Therapeutics was founded in 2021.
Resalis Therapeutics is headquartered in Italy.
Resalis Therapeutics operates in the following industries: Biotechnology, Health Care, Health and Wellness, Pharmaceutical.
Resalis Therapeutics has approximately 10 employees.
Resalis Therapeutics has completed 3 funding rounds, raising a total of $26.00M. The latest funding stage is Series A.
Top alternatives and competitors to Resalis Therapeutics include Avolynt, Inc., Ember Therapeutics, AZAFAROS B.V., Bilayer Therapeutics, Shanmu SHANMU. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Resalis Therapeutics and Avolynt, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Resalis Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy